MacroGenics, Inc.
MGNXHealthcare|Biotechnology|US
$2.33
+0.11 (+4.95%)
Tangible Book / Share
$0.67
Cash / Share
$2.73
Clinical Trials (54)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06014255 Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer | Prostate Cancer | P2 | Active | 219 | RCT, Open-label | Enoblituzumab |
| NCT02923180 Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer | Prostate Cancer | P2 | Active | 33 | Open-label | Enoblituzumab |
| NCT07071961 Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] | Colorectal Cancer, Regorafenib | P2 | Recruiting | 16 | Open-label | Regorafenib (CT), Lorigerlimab |
| NCT06227546 MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer | Extensive-stage Small-cell Lung Cancer | P2 | Active | 9 | Open-label | MGC018 |
| NCT07565155 Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency | Pancreatic Adenocarcinoma, Homologous Recombination Deficiency | P2 | Recruiting | 40 | Open-label | Lorigerlimab |
| NCT04425018 MARGetuximab Or Trastuzumab (MARGOT) | Breast Cancer, Stage II Breast Cancer | P2 | Active | 174 | RCT, Open-label | Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab |
| NCT05475171 Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Metastatic Cancer, Cervical Cancer | P2 | Recruiting | 60 | Open-label | Lorigerlimab |
| NCT06730347 A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma | P2 | Recruiting | 80 | Open-label | Lorigerlimab |
| NCT06242470 A Study of MGC026 in Participants With Advanced Solid Tumors | Advanced Solid Tumor, Advanced Cancer | P1 | Recruiting | 394 | Open-label | MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan |
| NCT07822399 A Study of MGC030 in Participants With Advanced Solid Tumors | Urothelial Cancer, GastroEsophageal Cancer | P1 | Recruiting | 314 | Open-label | MGC030 |
| NCT06723236 A Study of MGC028 in Participants With Advanced Solid Tumors | Advanced Solid Tumors, NSCLC Adenocarcinoma | P1 | Recruiting | 124 | Open-label | MGC028 |
| NCT05362773 A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Leukemia, Acute Myeloid, Myelodysplastic Syndromes | P1 | Active | 130 | Open-label | MGD024 |
| NCT00920582 Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P3 | Terminated | 254 | RCT, Double-blind | Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen |
| NCT02492711 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | HER-2 Positive Breast Cancer, Metastatic Neoplasm | P3 | Completed | 624 | RCT, Open-label | Margetuximab, Trastuzumab, Physician's choice of chemotherapy. |
| NCT00385697 The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P2P3 | Completed | 554 | RCT, Double-blind | Teplizumab, Placebo |
| NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | Gastric Cancer, Gastroesophageal Junction Cancer | P2P3 | Completed | 82 | RCT, Open-label | margetuximab, Retifanlimab, Tebotelimab, Trastuzumab |
| NCT04129320 Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | P2P3 | Withdrawn | — | Open-label | enoblituzumab, MGA012, MGD013 |
| NCT04622774 First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Completed | 56 | Open-label | IMGC936 |
| NCT05227131 Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer | Metastatic Breast Cancer, Advanced Breast Cancer | P2 | Withdrawn | — | Open-label | Margetuximab, Tucatinib, Capecitabine |
| NCT03729596 MGC018 With or Without MGA012 in Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer | P1P2 | Terminated | 143 | Open-label | vobramitamab duocarmazine |
| NCT07223567 A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer | Rectal Cancer, Rectal Cancer Recurrent | P2 | Withdrawn | — | Open-label | Regorafenib, Lorigerlimab |
| NCT02152956 Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) | AML | P1P2 | Terminated | 244 | Open-label | Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose, Ruxolitinib, Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose |
| NCT04582864 Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | Relapsed Acute Myeloid Leukemia | P2 | Terminated | 11 | Open-label | Flotetuzumab |
| NCT00954915 Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis | Psoriasis | P1P2 | Terminated | 1 | Open-label | teplizumab |
| NCT03531632 MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | Colorectal Cancer Metastatic | P1P2 | Completed | 38 | Open-label | MGD007 + MGA012 |
| NCT00625586 Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | Pancreatic Cancer | P2 | Terminated | 2 | Open-label | RAV12, Gemcitabine |
| NCT00927953 Treatment of West Nile Virus With MGAWN1 | West Nile Neuroinvasive Disease, West Nile Virus Infection | P2 | Terminated | 13 | RCT, Double-blind | MGAWN1, Placebo - normal saline |
| NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | P2 | Completed | 154 | RCT, Open-label | lorigerlimab, docetaxel, Prednisone |
| NCT02689284 Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | Gastric Cancer, Stomach Cancer | P1P2 | Completed | 95 | Open-label | Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab |
| NCT01828021 Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer | Breast Cancer | P2 | Completed | 25 | Open-label | Margetuximab |
| NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | P2 | Terminated | 192 | RCT, Open-label | vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide |
| NCT04634825 Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Head and Neck Cancer, Head and Neck Neoplasms | P2 | Terminated | 62 | Open-label | Enoblituzumab, Retifanlimab, Tebotelimab |
| NCT01148849 Safety Study of MGAH22 in HER2-positive Carcinomas | Breast Cancer, Gastric Cancer | P1 | Completed | 66 | Open-label | margetuximab |
| NCT00515385 A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults | West Nile Virus | P1 | Completed | 40 | RCT, Double-blind | MGAWN1, MGAWN1 |
| NCT03761017 MGD019 DART® Protein in Unresectable/Metastatic Cancer | Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic | P1 | Completed | 162 | Open-label | Lorigerlimab |
| NCT02475213 Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | Melanoma, Head and Neck Cancer | P1 | Completed | 146 | Open-label | Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab |
| NCT02982941 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Neuroblastoma, Rhabdomyosarcoma | P1 | Completed | 25 | Open-label | Enoblituzumab |
| NCT03219268 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Advanced Solid Tumors, Hematologic Neoplasms | P1 | Completed | 277 | Open-label | tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab |
| NCT02248805 Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | Colorectal Carcinoma | P1 | Completed | 95 | Open-label | MGD007 |
| NCT03406949 MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Advanced Solid Tumors | P1 | Completed | 25 | Open-label | obrindatamab, retifanlimab |
| NCT03570918 MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | HIV-1-infection | P1 | Completed | 21 | Open-label | MGD014 |
| NCT02376036 Phase 1 Study of MGD010 in Healthy Subjects | Healthy Subjects | P1 | Completed | 73 | RCT, Double-blind | MGD010, Placebo, Hepatitis A vaccine |
| NCT00101972 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | Cancer | P1 | Completed | 53 | Open-label | monoclonal antibody RAV12 |
| NCT01918930 Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | Melanoma | P1 | Terminated | 6 | Open-label | MGA271 |
| NCT01391143 Safety Study of MGA271 in Refractory Cancer | Prostate Cancer, Melanoma | P1 | Completed | 179 | Open-label | MGA271 |
| NCT05293496 A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | P1 | Completed | 31 | Open-label | vobramitamab duocarmazine, lorigerlimab |
| NCT01189422 Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes | Type 1 Diabetes Mellitus | P1 | Terminated | 1 | RCT, Double-blind | teplizumab or placebo |
| NCT02381314 Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | Melanoma, Non Small Cell Lung Cancer | P1 | Completed | 24 | Open-label | enoblituzumab plus ipilimumab |
| NCT02628535 Safety Study of MGD009 in B7-H3-expressing Tumors | Mesothelioma, Bladder Cancer | P1 | Terminated | 67 | Open-label | MGD009 |
| NCT05261191 A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy | Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human | P1 | Completed | 17 | Open-label | MGD020, MGD014 |
| NCT05506956 Post-transplant Flotetuzumab for AML | Leukemia, Myeloid, Acute | P1 | Completed | 3 | Open-label | Flotetuzumab |
| NCT01206504 Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure | West Nile Virus Infection | NO_LONGER_AVAILABLE | — | — | MGAWN1 | |
| NCT04678466 Flotetuzumab Expanded Access Program | Acute Myeloid Leukemia, AML | NO_LONGER_AVAILABLE | — | — | flotetuzumab | |
| NCT00870818 Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) | Type 1 Diabetes Mellitus | N/A | Terminated | 219 | Double-blind | — |